

Box No. VIII (ii) DECLARATION: ENTITLEMENT TO APPLY FOR AND BE GRANTED A PATENT

The declaration must conform to the standardized wording provided for in Section 212; see Notes to Boxes Nos. VIII, VIII (i) to (v) (in general) and the specific Notes to Box No. VIII (ii). If this Box is not used, this sheet should not be included in the request.

Declaration as to the applicant's entitlement, as at the international filing date, to apply for and be granted a patent (Rules 4.17(ii) and 51bis.1(a)(ii)), in a case where the declaration under Rule 4.17(iv) is not appropriate:

in relation to this International Application No. PCT/IB2019/05586 filed 08 July 2019

GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED is entitled to apply for and be granted a patent by virtue of the following:

an assignment from inventor(s):

Eugene L. STEWART to GlaxoSmithKline Intellectual Property Development Limited
dated: 06 August 2019

Michael Joseph BISHOP to GlaxoSmithKline Intellectual Property Development Limited
dated: 14 August 2019

Vincent J. COLANDREA to GlaxoSmithKline Intellectual Property Development Limited
dated: 12 August 2019

Iulia STRAMBEANU to GlaxoSmithKline Intellectual Property Development Limited
dated: 06 August 2019

Yuehu LI to GlaxoSmithKline Intellectual Property Development Limited
dated: 06 August 2019

Katherine Louisa WIDDOWSON to GlaxoSmithKline Intellectual Property Development Limited dated: 16 August 2019

and

FIMBRION THERAPEUTICS, INC. is entitled to apply for and be granted a patent by virtue of the following:

an assignment from inventor(s):

Laurel Kathryn MCGRANE to Fimbrion Therapeutics, Inc. dated: 18 June 2019

James Walter JANETKA to Fimbrion Therapeutics, Inc. dated: 19 June 2019

☐ This declaration is continued on the following sheet, "Continuation of Box No. VIII (ii)".